The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
Brexu-cel for patients with R/R B-ALL: 4-year follow-up from the ZUMA-3 trial
|
|
| Key learnings |
|
The median overall survival (OS) was 25.6 and 47.0 months for all phase I and phase II treated patients (n = 78), and patients who achieved a complete response (CR) or CR with incomplete count recovery (n = 57), respectively. |
|
Median OS was similar for all treated patients with that across various subgroups, including for patients aged <26 years (n = 15; 23.2 months), aged ≥26 years (n = 63; 26.0 months), and patients with ≥2 prior lines of therapy (n = 63; 25.4 months), and was higher in patients with 1 prior line of therapy (n = 15; 60.4 months). |
|
Among patients with ≥2 prior lines of therapy, patients with prior blinatumomab (n = 37) had a lower median OS vs those without (n = 26; 16.1 vs 47.0 months), and among responders, patients who did not proceed to subsequent allogeneic hematopoietic stem cell transplantation (allo-HSCT; n = 43) had a higher median OS than those who did (n = 14; 60.4 vs 36.3 months). |
|
The 48-month OS rate was 40% in all treated patients and was similar across most subgroups but lower in patients with prior blinatumomab (n = 38; 24%) and prior inotuzumab (n = 17; 21%) and higher in patients without prior blinatumomab (n = 38; 55%) and with 1 prior line of therapy (57%). |
|
No new safety signals were observed. |
|
These long-term survival outcomes confirm the benefit of brexu-cel in patients with R/R B-ALL, irrespective of age, number of prior therapy lines, or subsequent allo-HSCT. |
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
